24 March 2021 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ixekizumab in the NHS in England for patients with axial spondyloarthritis.

Ixekizumab is not recommended, within its marketing authorisation, for treating:

• active ankylosing spondylitis that has responded inadequately to conventional therapy in adults, or
• active non-radiographic axial spondyloarthritis with objective signs of inflammation (shown by elevated C-reactive protein or MRI, or both) that has responded inadequately to non-steroidal anti-inflammatory drugs in adults.

Read NICE appraisal consultation document for ixekizumab